Amedisys sees hospice growth as DOJ-UnitedHealth Group lawsuit looms

Amedisys sees hospice growth as DOJ-UnitedHealth Group lawsuit looms 
Hospice News; by Jim Parker; 2/27/25 
Amedisys Inc. (Nasdaq: AMED) saw hospice revenue growth during the fourth quarter of 2024 despite merger-related costs associated with its pending acquisition by UnitedHealth Group (NYSE: UNH). The company’s hospice business saw net service revenues of $21.29 million during the fourth quarter of 2024, up from $20.6 million year over year. For the full year 2024, net service revenue reached $82.58 million, an increase from $79.8 million in 2023. ... On a consolidated basis, company-wide net service revenue hit $59.8 million in Q4, up from $57 million in the prior year’s period. These results come as Amedisys and UnitedHealth Group are embroiled in a lawsuit by the U.S. Justice Department intended to block their potentially forthcoming acquisition due to antitrust concerns.